Clinical trials for - HIV Infection.

The European Union Clinical Trials Register allows you to search for protocol and results information on:

interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC

clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
Clinical Trials Information System (CTIS).

The EU Clinical Trials Register currently displays 44351 clinical trials with a EudraCT protocol, of which 7378 are clinical trials conducted with subjects less than 18 years old. The register also displays information on 18700 older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).

Examples: Cancer AND drug name. Pneumonia AND sponsor name.
How to search [pdf]

Advanced Search:

Search tools

Select Country:	Select Age Range:
Select Trial Status:	Select Trial Phase:
Select Gender:
Select Date Range: to
Select Rare Disease:
IMP with orphan designation in the indication
Orphan Designation Number:
Results Status:
Clear advanced search filters

Trials with a EudraCT protocol (4,404)
Paediatric studies in scope of Art45 of the Paediatric Regulation (0)

4,404 result(s) found for: - HIV Infection.. Displaying page 133 of 221.

EudraCT Number: 2017-004235-36	Sponsor Protocol Number: EWO-ISO-2017/2	Start Date*: 2018-09-27
Sponsor Name:Ewopharma AG
Full Title: A phase 4, randomized, open label multi-centre clinical study to evaluate efficacy of Isoprinosine® in female subjects with low-grade cervical dysplasia caused by HrHPV.
Medical condition: Low-grade cervical dysplasia caused by HrHPV
Disease:
Population Age: Adults		Gender: Female
Trial protocol: CZ (Completed)
Trial results: View results

EudraCT Number: 2015-004139-11

Sponsor Protocol Number: VAC52150EBL4001

Start Date*: Information not available in EudraCT

Sponsor Name:Janssen Vaccines & Prevention B.V.

Full Title: A Multicountry, Prospective, Clinical Safety Study of Subjects Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo

Medical condition: Ebola

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	10021881 - Infections and infestations	10014071	Ebola disease	PT

Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly

Gender: Male, Female

Trial protocol: GB (GB - no longer in EU/EEA) FR (Completed)

Trial results: View results

EudraCT Number: 2021-000842-16

Sponsor Protocol Number: PIRVACoV

Start Date*: 2021-03-18

Sponsor Name:Kristina Jakobsson

Full Title: Does PFAS-exposure modify the risk of COVID-19 infection or the immunological response after vaccination against SARS-CoV-2?

Medical condition: An observational study in healthy, differently PFAS-exposed subjects to check if PFAS modifies the immunological response to SARS-CoV-2 vaccination. The immunological response is quantified as SARS...

Disease:	Version	SOC Term	Classification Code	Term	Level
	23.0	100000004865	10084462	SARS-CoV-2 vaccination	LLT
	23.1	100000004865	10084465	COVID-19 vaccination	LLT

Population Age: Adults

Gender: Male, Female

Trial protocol: SE (Completed)

Trial results: (No results available)

EudraCT Number: 2020-001849-39	Sponsor Protocol Number: NETs-C19	Start Date*: 2020-05-18
Sponsor Name:Region Skåne
Full Title: Aerosolized DNase I for the treatment of severe respiratory failure in COVID-19 - a phase 2, randomized controlled trial
Medical condition: SARS-coronavirus-2 infection
Disease:
Population Age: Adults, Elderly		Gender: Male, Female
Trial protocol: SE (Completed)
Trial results: (No results available)

EudraCT Number: 2010-020551-31

Sponsor Protocol Number: NBMT-CMV

Start Date*: 2004-09-29

Sponsor Name:Nordic Bone and Marrow Transplantation Group

Full Title: Randomized study of oral ganciclovir versus i.v. ganciclovir for preemptive therapy of cytomegalovirus infection after stem cell transplantation.

Medical condition: First cytomegalovirus DNAemia after stem cell transplantation

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	12.1		10063310	Cytomegalovirus DNA test positive	LLT

Population Age: Adolescents, Under 18, Adults

Gender: Male, Female

Trial protocol: FI (Completed)

Trial results: (No results available)

EudraCT Number: 2020-001889-10	Sponsor Protocol Number: STOIC	Start Date*: 2020-06-02
Sponsor Name:University of Oxford, Clinical Trials and Research Governance
Full Title: Use of inhaled corticosteroids as treatment of early COVID-19 infection to prevent clinical deterioration and hospitalisation
Medical condition: COVID 19
Disease:
Population Age: Adults, Elderly		Gender: Male, Female
Trial protocol: GB (GB - no longer in EU/EEA)
Trial results: View results

EudraCT Number: 2022-000845-34	Sponsor Protocol Number: B1851196	Start Date*: 2022-03-24
Sponsor Name:Pfizer Inc.
Full Title: A COHORT STUDY TO EVALUATE IMMUNOGENICITY FOR CHILDREN AGED 5 MONTHS TO ≤60 MONTHS AT THE TIME OF CLINICAL PNEUMONIA DIAGNOSIS
Medical condition: Pneumococcal Infections
Disease:
Population Age: Infants and toddlers, Children, Under 18		Gender: Male, Female
Trial protocol: Outside EU/EEA
Trial results: View results

EudraCT Number: 2017-002468-41

Sponsor Protocol Number: Dial-1

Start Date*: 2018-06-21

Sponsor Name:University Medical Center of the Johannes Gutenberg- University Mainz

Full Title: A phase I/II multicenter, open-label Study of DKN-01 to investigate the anti-tumor activity and safety of DKN-01 in Patients with Hepatocellular Carcinoma and WNT signaling Alterations

Medical condition: Hepatocellular Carcinoma

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10073071	Hepatocellular carcinoma	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Prematurely Ended)

Trial results: View results

EudraCT Number: 2007-006539-29	Sponsor Protocol Number: 0	Start Date*: 2008-03-14
Sponsor Name:Dept of Rheumatology, Lund University Hospital, Lund, Sweden
Full Title: Effects of different anti-rheumatic treatments of arthritis on antibody response following pneumococcal vaccination using Prevenar
Medical condition: Patients with rheumatic diseases (rheumatoid arthritis and spondyloarthripaties) who are going to be vaccinated with Prevenar vaccine in order to study the serological responses to two pneumococc...
Disease:
Population Age: Adults, Elderly		Gender: Male, Female
Trial protocol: SE (Completed)
Trial results: (No results available)

EudraCT Number: 2008-006083-11	Sponsor Protocol Number: 110699 to 110704	Start Date*: 2009-03-23
Sponsor Name:GlaxoSmithKline Biologicals
Full Title: An open multicentre, multicountry study to evaluate long-term antibody persistence and immune memory between Years 11 and 15 after the primary study HAB-084 in which healthy adolescents were vaccin...
Medical condition: Adult subjects who received a primary vaccination course with Twinrix Adult following a two-dose schedule or Twinrix Junior following a three-dose schedule as adolescents (12-15 years) approximate...
Disease:
Population Age: Adults		Gender: Male, Female
Trial protocol: BE (Completed) CZ (Completed)
Trial results: View results

EudraCT Number: 2011-005627-40	Sponsor Protocol Number: P12.130	Start Date*: 2012-09-19
Sponsor Name:
Full Title: Comparison of effectiveness of hepatitis B revaccination schemes in healthy non-responders
Medical condition: previous non-response to hepatitis B vaccine (3 vaccinations, standard schedule)
Disease:
Population Age: Adults		Gender: Male, Female
Trial protocol: NL (Completed)
Trial results: View results

EudraCT Number: 2004-004727-36	Sponsor Protocol Number: NR 8230-3/2004	Start Date*: 2005-02-10
Sponsor Name:Charles University, 3rd Faculty of Medicine
Full Title: Influence of low-dose i.v. growth hormone treatment together with glutamine supplementation in late-phase critically ill patient after multiple injury. A pilot study.
Medical condition: Prolonged phase of critical illness after severe multiple trauma
Disease:
Population Age: Adults		Gender: Female
Trial protocol: CZ (Completed)
Trial results: (No results available)

EudraCT Number: 2022-003581-20	Sponsor Protocol Number: ALPHA	Start Date*: 2023-03-21
Sponsor Name:Medical University Vienna
Full Title: Albendazole pharmacokinetics in plasma, intra-cystic fluid, and cystic tissue of human cystic and alveolar echinococcosis
Medical condition: Albendazole is an orally administered broad-spectrum anthelmintic Drug used in treatment of human alveolar and cystic echinococcosis. To date, data on albendazole and tissue pharmacokinetics are li...
Disease:
Population Age: Adults, Elderly		Gender: Male, Female
Trial protocol: AT (Ongoing)
Trial results: (No results available)

EudraCT Number: 2020-001498-63

Sponsor Protocol Number: BIO101-CL05

Start Date*: 2020-07-22

Sponsor Name:Biophytis S.A.

Full Title: Adaptive design phase 2 to 3, randomized, double- blind, multicenter, to evaluate the safety, efficacy, pharmacokinetics and pharmacodynamics of BIO101 in the prevention of the respiratory deterior...

Medical condition: Confirmed infection with SARS-CoV-2 (COVID-19)

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	10021881 - Infections and infestations	10047465	Viral infections NEC	HLT
	23.0	10021881 - Infections and infestations	10084268	COVID-19	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: FR (Completed) BE (Completed) GB (GB - no longer in EU/EEA)

Trial results: (No results available)

EudraCT Number: 2017-002694-19	Sponsor Protocol Number: 62449	Start Date*: 2018-02-22
Sponsor Name:Radboud University Medical Centre
Full Title: Mifepristone and misoprostol versus misoprostol alone for uterine evacuation after early pregnancy failure: a randomized double blind placebo-controlled comparison (M&M trial).
Medical condition: Early pregnancy failure
Disease:
Population Age: Adults		Gender: Female
Trial protocol: NL (Prematurely Ended)
Trial results: View results

EudraCT Number: 2018-003975-36

Sponsor Protocol Number: 9766-CL-0107

Start Date*: 2019-12-13

Sponsor Name:Astellas Pharma Global Development, Inc.

Full Title: A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillos...

Medical condition: Invasive Aspergillosis and Invasive Mucormycosis

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.1	100000004862	10062642	Invasive mycosis	LLT

Population Age: Infants and toddlers, Children, Adolescents, Under 18

Gender: Male, Female

Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) DE (Completed) ES (Ongoing) Outside EU/EEA

Trial results: View results

EudraCT Number: 2020-005887-70	Sponsor Protocol Number: REMED	Start Date*: 2021-01-28
Sponsor Name:Fakultní nemocnice Brno
Full Title: Effect of dexamethasone in patients with ARDS and COVID-19 – prospective, multi-centre, open-label, parallel-group, randomized controlled trial
Medical condition: Acute respiratory distress syndrome (ARDS) associated with COVID-19 pneumonia
Disease:
Population Age: Adults, Elderly		Gender: Male, Female
Trial protocol: CZ (Completed)
Trial results: (No results available)

EudraCT Number: 2009-011889-28	Sponsor Protocol Number: AMLSG09-09	Start Date*: 2010-02-08
Sponsor Name:University of Ulm
Full Title: Phase III study of chemotherapy in combination with ATRA with or without gemtuzumab ozogamicin in patients with acute myeloid leukemia and NPM1 gene mutation
Medical condition: adult patients with AML and NPM1 mutation
Disease:
Population Age: Adults, Elderly		Gender: Male, Female
Trial protocol: DE (Completed) AT (Completed)
Trial results: View results

EudraCT Number: 2020-005849-16

Sponsor Protocol Number: KIN001-203

Start Date*: 2021-03-09

Sponsor Name:Kinarus AG

Full Title: An 8-week double-blind, randomized, placebo-controlled, phase II study evaluating the effects of oral pamapimod 150 mg with pioglitazone 10 mg daily on COVID-19 development in hospitalized patient...

Medical condition: COVID-19 development in hospitalized patients infected with SARS-CoV-2

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	23.0	100000004862	10084272	SARS-CoV-2 infection	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Prematurely Ended) BG (Prematurely Ended)

Trial results: (No results available)

EudraCT Number: 2020-001156-18	Sponsor Protocol Number: PanCOVID19	Start Date*: 2020-03-27
Sponsor Name:Fundación para la investigación Biomedica Hospital Universitario La Paz
Full Title: Randomized clinical trial to evaluate the efficacy of different treatments in patients with COVID-19 who require hospitalization
Medical condition: Patients infected with COVID19
Disease:
Population Age: Adults		Gender: Male, Female
Trial protocol: ES (Ongoing)
Trial results: View results

Subscribe to this Search
To subscribe to the RSS feed for this search click here

. This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.

Download Options:
Number of Trials to download:

Download Content:

Download Format:


Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.

Query did not match any studies.

For support, Contact us.

The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

European Medicines Agency © 1995-Fri Jul 25 05:22:31 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands

Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
United Kingdom
Outside EU/EEA